Raymon Heather 4

What Happened

• Raymon Heather, Senior Vice President of Research and Development at Artiva Biotherapeutics (ARTV), was granted 46,000 restricted stock units (RSUs) on 2026-02-15 (reported on a Form 4 filed 2026-02-18). The RSUs were granted at $0.00 per share (award/compensation).
• To satisfy income tax withholding associated with vesting, Artiva withheld 1,521 shares (treated as a disposition) at $4.00 per share, totaling $6,084.

Key Details

• Transaction date: 2026-02-15; Form 4 filing date: 2026-02-18.
• Grant (code A): 46,000 RSUs, acquisition price reported as $0.00.
• Tax withholding (code F): 1,521 shares withheld at $4.00 = $6,084 (disposition to cover tax obligations).
• Footnotes: F1 — RSU award granted under the Issuer's 2024 Equity Incentive Plan. F2 — Shares withheld to satisfy income tax obligations on vesting.
• Shares owned after the transaction: Not specified in the provided summary of the filing.
• Filing timeliness: Filing date and transaction date are shown; no late-filing flag was provided in the supplied data.

Context

• This is a compensation-related award (RSUs), not an open-market purchase or a stock sale. Tax withholding via share retention is routine for vested equity awards and reduces the number of shares actually delivered to the insider.
• Such grants are common for executives and typically reflect compensation/retention, not a direct buy/sell signal about the executive's market view.